MX358757B - Pirrolobenzodiazepinas y conjugados dirigidos. - Google Patents
Pirrolobenzodiazepinas y conjugados dirigidos.Info
- Publication number
- MX358757B MX358757B MX2014004555A MX2014004555A MX358757B MX 358757 B MX358757 B MX 358757B MX 2014004555 A MX2014004555 A MX 2014004555A MX 2014004555 A MX2014004555 A MX 2014004555A MX 358757 B MX358757 B MX 358757B
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- pyrrolobenzodiazepines
- targeted conjugates
- biological properties
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Esta invención se relaciona con pirrolobenzodiazepinas (PBDs), en particular dímeros de pirrolobenzodiazepinas que tienen un enlace doble C2-C3 y un grupo arilo en la posición C2 en cada unidad monomérica, y su inclusión en conjugados dirigidos. Los diferentes grupos sustituyentes pueden ofrecer ventajas en la preparación y uso de los compuestos, particularmente en sus propiedades biológicas y la síntesis de conjugados, y las propiedades biológicas de esos conjugados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547195P | 2011-10-14 | 2011-10-14 | |
PCT/US2012/059870 WO2013055993A1 (en) | 2011-10-14 | 2012-10-12 | Pyrrolobenzodiazepines and targeted conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014004555A MX2014004555A (es) | 2015-02-05 |
MX358757B true MX358757B (es) | 2018-09-03 |
Family
ID=48082466
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014004555A MX358757B (es) | 2011-10-14 | 2012-10-12 | Pirrolobenzodiazepinas y conjugados dirigidos. |
MX2020010616A MX2020010616A (es) | 2011-10-14 | 2014-04-14 | Metodos para preparar pirrolobenzodiazepinas y conjugados dirigidos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010616A MX2020010616A (es) | 2011-10-14 | 2014-04-14 | Metodos para preparar pirrolobenzodiazepinas y conjugados dirigidos. |
Country Status (15)
Country | Link |
---|---|
US (3) | US9387259B2 (es) |
EP (2) | EP2753178B1 (es) |
JP (2) | JP6399930B2 (es) |
KR (1) | KR101961976B1 (es) |
CN (1) | CN103997893B (es) |
AU (1) | AU2012322613B2 (es) |
BR (2) | BR112014009055B1 (es) |
CA (1) | CA2850375C (es) |
EA (2) | EA026643B1 (es) |
ES (1) | ES2660233T3 (es) |
HK (1) | HK1253715A1 (es) |
IL (1) | IL231797A (es) |
MX (2) | MX358757B (es) |
WO (1) | WO2013055993A1 (es) |
ZA (1) | ZA201402404B (es) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
KR101671360B1 (ko) | 2010-04-15 | 2016-11-01 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
BR112014006703A8 (pt) | 2011-09-20 | 2018-01-09 | Spirogen Sarl | "pirrolobenzodiazepinas |
ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
EA026643B1 (ru) | 2011-10-14 | 2017-04-28 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
JP6170497B2 (ja) | 2011-10-14 | 2017-07-26 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン |
EA027386B1 (ru) * | 2011-10-14 | 2017-07-31 | Медимьюн Лимитед | Пирролобензодиазепины |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
BR112015008173A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolobenzodiazepina-anticorpo anti-psma |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
SI2839860T1 (sl) | 2012-10-12 | 2019-07-31 | MedImmune Limited, | Pirolobenzodiazepini in njihovi konjugati |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
TR201902494T4 (tr) | 2012-10-12 | 2019-03-21 | Medimmune Ltd | Pirrolobenzodiazepinler ve onların konjugatları. |
SI2906296T1 (en) | 2012-10-12 | 2018-06-29 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN105189546B (zh) | 2013-03-13 | 2022-09-02 | 西雅图基因公司 | 环糊精和抗体-药物偶联物制剂 |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3441072B1 (en) | 2013-03-13 | 2020-12-30 | Seagen Inc. | Activated carbon filtration for purification of benzodiazepine adcs |
MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
MY183572A (en) | 2013-03-15 | 2021-02-26 | Regeneron Pharma | Biologically active molecules, conjugates thereof, and therapeutic uses |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
KR102645430B1 (ko) | 2013-10-15 | 2024-03-11 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
KR20220127364A (ko) | 2013-12-19 | 2022-09-19 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
RS59077B1 (sr) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
GB201409653D0 (en) * | 2014-05-30 | 2014-07-16 | Stell Dr Anneliese | Pyrrolobenzodiazepine therapeutic agents |
EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3191135B1 (en) | 2014-09-12 | 2020-08-19 | Genentech, Inc. | Anti-her2 antibodies and immunoconjugates |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
CA2973354A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
CA2973355A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using |
JP6876628B2 (ja) * | 2015-03-05 | 2021-05-26 | ペーター ウント トラウドル エンゲルホーン−シュティフトゥング ツア フェアデルング デア レーベンスヴィッセンシャフテン | 細胞表面上にペプチドを提示するためのシステム |
KR20170131587A (ko) | 2015-03-27 | 2017-11-29 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
CA2990030A1 (en) | 2015-06-23 | 2016-12-29 | Bristol-Myers Squibb Company | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses |
EA038973B1 (ru) | 2015-07-06 | 2021-11-17 | Ридженерон Фармасьютикалз, Инк. | Полиспецифические антигенсвязывающие молекулы и их применения |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
CA3006000A1 (en) | 2015-12-04 | 2017-06-08 | Seattle Genetics, Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
US9950076B2 (en) | 2016-01-25 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
EP3458069B1 (en) | 2016-05-18 | 2023-07-05 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
MX2018015683A (es) | 2016-06-17 | 2019-05-27 | Magenta Therapeutics Inc | Composiciones y métodos para el agotamiento de células. |
EP3475284B1 (en) | 2016-06-24 | 2022-11-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
US20190328900A1 (en) | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
KR102520731B1 (ko) | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
PT3515487T (pt) | 2016-09-23 | 2023-08-24 | Regeneron Pharma | Anticorpos anti-muc16-cd3 biespecíficos e conjugados antimuc16- fármacos |
WO2018071455A1 (en) | 2016-10-10 | 2018-04-19 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepine (iqb)-1(chloromethyl)-2,3-dihydro-1h-benzo[e]indole (cbi) dimers |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
MX2019005330A (es) | 2016-11-08 | 2019-09-11 | Regeneron Pharma | Esteroides y conjugados de proteinas de los mismos. |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
SG10202102897PA (en) | 2017-01-20 | 2021-04-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
UA125198C2 (uk) | 2017-02-08 | 2022-01-26 | Ейдісі Терапьютікс Са | Кон'югати піролобензодіазепін-антитіло |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
JP7181181B2 (ja) | 2017-02-28 | 2022-11-30 | 第一三共株式会社 | 抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法 |
JP2020512312A (ja) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体 |
SI3612537T1 (sl) | 2017-04-18 | 2022-10-28 | Medimmune Limited | Konjugati pirolobenzodiazepina |
CN110536703A (zh) | 2017-04-20 | 2019-12-03 | Adc治疗有限公司 | 使用抗axl抗体-药物缀合物的组合疗法 |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
EP3624894A1 (en) | 2017-05-18 | 2020-03-25 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
IL270595B2 (en) | 2017-05-18 | 2023-09-01 | Regeneron Pharma | Bi-octahydrophenanthrene carboxamides and their protein conjugates |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
CN111065638B (zh) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
TW202405006A (zh) | 2017-09-29 | 2024-02-01 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物複合體 |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
AU2018365946A1 (en) | 2017-11-07 | 2020-05-14 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
EP3710066B1 (en) * | 2017-11-14 | 2022-06-08 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US20220305127A1 (en) | 2017-12-21 | 2022-09-29 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
WO2019136487A2 (en) | 2018-01-08 | 2019-07-11 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
CN112074538A (zh) | 2018-04-30 | 2020-12-11 | 瑞泽恩制药公司 | 结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途 |
AU2019265703A1 (en) | 2018-05-09 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
AU2019269685A1 (en) | 2018-05-17 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Anti-CD63 antibodies, conjugates, and uses thereof |
EA202092909A1 (ru) | 2018-05-29 | 2021-04-07 | Интоселл, Инк. | Новый бензодиазепин, его производные и применение |
US20220072144A1 (en) | 2018-09-20 | 2022-03-10 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
US20220080052A1 (en) | 2018-11-20 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
EP3897841A1 (en) | 2018-12-21 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Rifamycin analogs and antibody-drug conjugates thereof |
CA3124106A1 (en) | 2018-12-21 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
BR112021013464A2 (pt) | 2019-01-08 | 2021-09-21 | Regeneron Pharmaceuticals, Inc. | Ligantes sem traço e conjugados de proteína dos mesmos |
MX2021010114A (es) | 2019-02-21 | 2021-12-10 | Regeneron Pharma | Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met. |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
WO2021055350A1 (en) | 2019-09-16 | 2021-03-25 | Regeneron Pharmaceuticals, Inc. | Radiolabeled met binding proteins for immuno-pet imaging |
US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
US20240123081A1 (en) | 2019-10-25 | 2024-04-18 | Medimmune, Llc | Branched moiety for use in conjugates |
CN115348874A (zh) | 2020-01-24 | 2022-11-15 | 里珍纳龙药品有限公司 | 蛋白质-抗病毒化合物偶联物 |
MX2022010599A (es) | 2020-02-28 | 2022-09-09 | Regeneron Pharma | Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos. |
WO2021211984A1 (en) | 2020-04-16 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Diels-alder conjugation methods |
CA3185601A1 (en) | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
TW202216212A (zh) | 2020-07-17 | 2022-05-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
CA3191304A1 (en) | 2020-09-14 | 2022-03-17 | Amy Han | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
MX2023004434A (es) | 2020-10-22 | 2023-05-08 | Regeneron Pharma | Anticuerpos anti-fgfr2 y metodos para usarlos. |
IL307947A (en) | 2021-07-28 | 2023-12-01 | Regeneron Pharma | An antiviral compound of proteins |
WO2023129518A1 (en) | 2021-12-29 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
WO2023137026A1 (en) | 2022-01-12 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
WO2023137443A1 (en) | 2022-01-14 | 2023-07-20 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
WO2023173132A1 (en) | 2022-03-11 | 2023-09-14 | Regeneron Pharmaceuticals, Inc. | Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
WO2024020164A2 (en) | 2022-07-21 | 2024-01-25 | Firefly Bio, Inc. | Glucocorticoid receptor agonists and conjugates thereof |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361742A (en) | 1964-12-07 | 1968-01-02 | Hoffmann La Roche | 5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides |
US3523941A (en) | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
US3524849A (en) | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
JPS4843755B1 (es) | 1969-06-26 | 1973-12-20 | ||
IL33558A (en) | 1968-12-30 | 1973-10-25 | Fujisawa Pharmaceutical Co | Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production |
FR2027356A1 (en) | 1968-12-30 | 1970-09-25 | Fujisawa Pharmaceutical Co | Benzodiazepinone antibiotics |
JPS5382792U (es) | 1976-12-10 | 1978-07-08 | ||
JPS6053033B2 (ja) | 1976-12-28 | 1985-11-22 | 財団法人微生物化学研究会 | 新制癌抗生物質マゼスラマイシン及びその製造方法 |
JPS585916B2 (ja) | 1977-12-27 | 1983-02-02 | 株式会社ミドリ十字 | 新規ベンゾジアゼピン系化合物 |
JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
JPS57131791A (en) | 1980-12-31 | 1982-08-14 | Fujisawa Pharmaceut Co Ltd | Benzodiazepine derivative and its preparation |
JPH0353356Y2 (es) | 1981-02-06 | 1991-11-21 | ||
CA1184175A (en) | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
CA1173441A (en) | 1981-02-27 | 1984-08-28 | Hoffmann-La Roche Limited | Imidazodiazepines |
CA1185602A (en) | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質dc−81およびその製造法 |
JPS58180487U (ja) | 1982-05-28 | 1983-12-02 | 松下電工株式会社 | 光線式報知器の組立体 |
US4427588A (en) | 1982-11-08 | 1984-01-24 | Bristol-Myers Company | Process for conversion of oxotomaymycin to tomaymycin |
US4427587A (en) | 1982-11-10 | 1984-01-24 | Bristol-Myers Company | Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B |
JPS59152329A (ja) | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | 局所障害抑制剤 |
FR2586683B1 (fr) | 1985-08-29 | 1988-07-01 | Centre Nat Rech Scient | Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments |
JP2660201B2 (ja) | 1988-08-05 | 1997-10-08 | 塩野義製薬株式会社 | 新規ピロロ[1,4]ベンゾジアゼピン誘導体および老人性痴呆薬 |
FR2676230B1 (fr) | 1991-05-07 | 1993-08-27 | Centre Nat Rech Scient | Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant. |
GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
FR2696176B1 (fr) | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
GB9316162D0 (en) | 1993-08-04 | 1993-09-22 | Zeneca Ltd | Fungicides |
ATE349722T1 (de) | 1998-07-08 | 2007-01-15 | E Ink Corp | Verbesserte farbige mikroverkapselte elektrophoretische anzeige |
GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
PT1193270E (pt) * | 1998-08-27 | 2003-10-31 | Spirogen Ltd | Pirrolobenzodiazepinas |
GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
ES2254492T3 (es) | 2000-09-19 | 2006-06-16 | Moses Lee | Composiciones y procedimientos de uso de analogos aquirales de cc-1065 y de duocarmicinas. |
US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
US6660856B2 (en) | 2002-03-08 | 2003-12-09 | Kaohsiung Medical University | Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
FR2846966A1 (fr) | 2002-11-07 | 2004-05-14 | Fournier Lab Sa | Derive du 4-methyl-2-oxo-2h-1-benzopyran-7-yl 5-thio-beta-d- xylopyranoside, son procede de preparation et composition pharmaceutique le contenant |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
CA2520898C (en) | 2003-03-31 | 2009-10-20 | Council Of Scientific And Industrial Research | Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
PL1720881T3 (pl) | 2004-03-01 | 2013-05-31 | Medimmune Ltd | Pochodne 11-hydroksy-5h-pirolo[2,1-c][1,4]benzodiazepin-5-onu jako kluczowe związki pośrednie do otrzymywania C2 podstawionych pirolobenzodiazepin |
GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
DE102004010943A1 (de) | 2004-03-03 | 2005-09-29 | Degussa Ag | Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten |
WO2005085260A1 (en) | 2004-03-09 | 2005-09-15 | Spirogen Limited | Pyrrolobenzodiazepines |
FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
GB0410725D0 (en) * | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
EP1831418A2 (en) | 2004-12-24 | 2007-09-12 | Showa Denko Kabushiki Kaisha | Production method of thermoelectric semiconductor alloy, thermoelectric conversion module and thermoelectric power generating device |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
PT1879901E (pt) * | 2005-04-21 | 2010-03-29 | Spirogen Ltd | Pirrolobenzodiazepinas |
US20070154906A1 (en) | 2005-10-05 | 2007-07-05 | Spirogen Ltd. | Methods to identify therapeutic candidates |
ATE427949T1 (de) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
PL1813614T3 (pl) | 2006-01-25 | 2012-03-30 | Sanofi Sa | Środki cytotoksyczne zawierające nowe pochodne tomaymycyny |
JP5622390B2 (ja) | 2006-07-18 | 2014-11-12 | サノフイ | 癌治療用対epha2アンタゴニスト抗体 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2008050140A2 (en) | 2006-10-27 | 2008-05-02 | Spirogen Limited | Compounds for treatment of parasitic infection |
ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
KR101641345B1 (ko) * | 2007-10-12 | 2016-07-20 | 시애틀 지네틱스, 인크. | 항체-약물 접합체를 이용한 병용 요법 |
GB0722088D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0722087D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Polyamides |
NO2842575T3 (es) | 2008-03-18 | 2018-02-24 | ||
US20110010249A1 (en) | 2008-03-21 | 2011-01-13 | Oexman Robert D | Methods and apparatuses for providing a sleep system having customized zoned support and zoned comfort |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
RU2683325C2 (ru) | 2009-02-05 | 2019-03-28 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
CA2775350A1 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
EP2534158B1 (en) | 2010-02-09 | 2014-01-08 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
KR101671360B1 (ko) | 2010-04-15 | 2016-11-01 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
ES2717657T3 (es) | 2011-02-15 | 2019-06-24 | Immunogen Inc | Métodos para la preparación de conjugados |
BR112014006703A8 (pt) | 2011-09-20 | 2018-01-09 | Spirogen Sarl | "pirrolobenzodiazepinas |
EA026643B1 (ru) | 2011-10-14 | 2017-04-28 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
JP6170497B2 (ja) | 2011-10-14 | 2017-07-26 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン |
EP2750713B1 (en) | 2011-10-14 | 2015-09-16 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
AU2012322933B2 (en) | 2011-10-14 | 2017-02-02 | Medimmune Limited | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
EA027386B1 (ru) | 2011-10-14 | 2017-07-31 | Медимьюн Лимитед | Пирролобензодиазепины |
IN2014MN02092A (es) | 2012-04-30 | 2015-09-04 | Spirogen Sarl | |
JP6125614B2 (ja) | 2012-04-30 | 2017-05-10 | ユーシーエル ビジネス ピーエルシー | ピロロベンゾジアゼピン |
MX2015000359A (es) | 2012-07-09 | 2015-04-14 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd79b. |
MX2015000357A (es) | 2012-07-09 | 2015-05-12 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd22. |
CN104717979A (zh) | 2012-08-02 | 2015-06-17 | 基因泰克公司 | 抗etbr抗体和免疫偶联物 |
EP2906252B1 (en) | 2012-10-12 | 2017-06-14 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
JP6392763B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
BR112015008173A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolobenzodiazepina-anticorpo anti-psma |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
SI2906296T1 (en) | 2012-10-12 | 2018-06-29 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
SI2839860T1 (sl) | 2012-10-12 | 2019-07-31 | MedImmune Limited, | Pirolobenzodiazepini in njihovi konjugati |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
TR201902494T4 (tr) | 2012-10-12 | 2019-03-21 | Medimmune Ltd | Pirrolobenzodiazepinler ve onların konjugatları. |
US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
ME03394B (me) | 2013-02-22 | 2020-01-20 | Medimmune Ltd | Antidllз-antitelo-pbd konjugati i nihovа upotreba |
AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
MX364330B (es) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US20160256561A1 (en) | 2013-10-11 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
JP6681838B2 (ja) | 2013-12-16 | 2020-04-15 | ジェネンテック, インコーポレイテッド | ペプチド模倣薬化合物及びその抗体−薬剤複合体 |
GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
-
2012
- 2012-10-12 EA EA201490582A patent/EA026643B1/ru unknown
- 2012-10-12 JP JP2014535898A patent/JP6399930B2/ja active Active
- 2012-10-12 BR BR112014009055-6A patent/BR112014009055B1/pt active IP Right Grant
- 2012-10-12 CA CA2850375A patent/CA2850375C/en active Active
- 2012-10-12 KR KR1020147012118A patent/KR101961976B1/ko active IP Right Grant
- 2012-10-12 EA EA201692215A patent/EA036202B1/ru unknown
- 2012-10-12 EP EP12840422.5A patent/EP2753178B1/en active Active
- 2012-10-12 WO PCT/US2012/059870 patent/WO2013055993A1/en active Application Filing
- 2012-10-12 US US14/351,172 patent/US9387259B2/en active Active
- 2012-10-12 ES ES12840422.5T patent/ES2660233T3/es active Active
- 2012-10-12 AU AU2012322613A patent/AU2012322613B2/en active Active
- 2012-10-12 CN CN201280062297.3A patent/CN103997893B/zh active Active
- 2012-10-12 BR BR122021017842-9A patent/BR122021017842B1/pt active IP Right Grant
- 2012-10-12 MX MX2014004555A patent/MX358757B/es active IP Right Grant
- 2012-10-12 EP EP17198214.3A patent/EP3309162A1/en active Pending
-
2014
- 2014-03-30 IL IL231797A patent/IL231797A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02404A patent/ZA201402404B/en unknown
- 2014-04-14 MX MX2020010616A patent/MX2020010616A/es unknown
-
2016
- 2016-06-15 US US15/182,649 patent/US9707301B2/en active Active
-
2017
- 2017-06-27 US US15/634,883 patent/US10329352B2/en active Active
-
2018
- 2018-05-17 JP JP2018095724A patent/JP6599509B2/ja active Active
- 2018-10-10 HK HK18112863.9A patent/HK1253715A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010616A (es) | Metodos para preparar pirrolobenzodiazepinas y conjugados dirigidos. | |
ZA201201397B (en) | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
IL245889B (en) | Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases | |
MX2012000575A (es) | Conjugados de epsilon-polilisina y uso de los mismos. | |
WO2011123820A3 (en) | Single isomeric conjugates of rhodamine dyes | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
IL222269A (en) | Target-targeted pyrolobenzodiazepine couplings | |
NZ729044A (en) | 4-1bb binding molecules | |
IL228988A (en) | Antibody preparations for the treatment of vaccine-related diseases | |
WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
BR112013019913A2 (pt) | derivados de benzodiazepina citotóxicos. | |
EA201200617A1 (ru) | Полимеры на основе циклодекстрина для доставки лекарственных средств | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
MY159197A (en) | Anticancer derivatives, preparation thereof and therapeutic use thereof | |
JO2721B1 (en) | Derivatives of artemisia plant and its preparations and therapeutic applications | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
EP2576575A4 (en) | PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF | |
MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
UA109646C2 (uk) | Терапевтичне застосування кон'югатів білка з полімером | |
UA60741U (en) | Derivatives of 8-selenoxospiro[3,5,7,11-tetraazatricyclo[7.3.1.02,7]tridec-2-ene-13,4'-cyclohexane]-1,9-dicarbonitriles | |
TN2013000014A1 (en) | Anticancer derivatives, preparation thereof and therapeutic use thereof | |
UA105091C2 (uk) | 6-n-заміщені похідні 1,3-диметилурацил-5-карбальдегіду | |
ITMI20111766A1 (it) | Manufatto per la preparazione di articoli imbottiti. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: SEATTLE GENETICS, INC. |
|
FG | Grant or registration |